international journal of trichology...platelet-rich plasma (prp) treatment has gained popularity...

InternationalJournalofTrichologyIntJTrichology.10(1):1-10

AMeta-analysisOnEvidenceOfPlatelet-richPlasmaforAndrogeneticAlopeciaSalvatoreGiordano,MarcoRomeo1,PietrodiSumma2,Andre'Salval,PetteriLankinen3

DepartmentofPlasticandGeneralSurgery,TurkuUniversityHospital,UniversityofTurku,Turku,Finland1.DepartmentofPlasticSurgery,JiménezDiazFoundation,AutonomousUniversityofMadrid,Madrid,Spain2.DepartmentofPlasticSurgery,CanniesburnPlasticSurgeryUnit,GlasgowRoyalInfirmary,GlasgowG40SF,UnitedKingdom3.DepartmentofOrthopaedicsandTraumatology,TurkuUniversityHospital,UniversityofTurku,Turku,Finland

Addressforcorrespondence:Dr.SalvatoreGiordano,DepartmentofPlasticandGeneralSurgery,TurkuUniversityHospital,OS299,PL52,20521,Turku,Finland.E-mail:salvatore.giordano@gmail.com,salvatore.giordano@tyks.fi

Copyright:©2018InternationalJournalofTrichologyDOI:10.4103/ijt.ijt_74_16Publishedinprint:Jan-Feb2018

Abstract

Background:Platelet-richplasma(PRP)treatmenthasgainedpopularityamongdifferentsurgicalspecialitiesforimprovingvariousconditions.Androgeneticalopecia(AGA)isacommondisorder,withpossiblepsychosocialimplications.PlasticsurgeonshaveincreasedthepracticeofPRPinjectionsforhairrestoration.Ameta-analysisonthistopicwasperformedcomparinglocalinjectionofPRPversuscontroltoinvestigatetheefficacyoflocalPRPinjectionsinAGA.

Methods:Weperformedasystematicliteraturesearch.Theincreaseinnumberofhairswastheprimaryoutcome.Secondaryoutcomesweretheincreaseofhairthicknessandthepercentageincreaseinhairnumberandthickness.

Results:Sevenstudiesinvolving194patientswereretrievedandincludedinthepresentanalysis.Asignificantlylocallyincreasedhairnumberpercm2wasobservedafterPRPinjectionsversuscontrol(meandifference[MD]14.38,95%confidenceinterval[CI]6.38–22.38,P<0.001).Similarly,asignificantlyincreasedhairthicknesscross-sectionper10−4mm2(MD0.22,95%CI0.07–0.38,P=0.005)favoringPRPgroup.Thepooledresultsdidnotshowasignificantpercentageincreaseinhairnumber(MD18.79%,95%CI−8.50–46.08,P=0.18),neitherhairthickness(MD32.63%,95%CI−16.23–81.48,P=0.19)amongpatientstreatedwithPRP.

Conclusion:LocalinjectionofPRPforandrogenicalopeciamightbeassociatedwithanincreasednumberofhairsinthetreatedareaswithminimalmorbidity,butthereisclearlyalackofscientificevidenceonthistreatmentmodality.FurtherstudiesareneededtoevaluatetheefficacyofPRPforAGA.

INTRODUCTIONAndrogeneticalopecia(AGA)alsoknownasmalepatternbaldnessisthemostcommonhairlossdisorderaffectingupto80%ofmenandupto40%ofwomenwithCaucasianheritage.Forpatients,alopeciacausesmajordiscomfortduetoanalteredappearancewithsignificantimplicationsindailylivingandpossibleleadingtodepressionandanxietysymptoms.[1]

Platelet-richplasma(PRP)injectionsforhairrestorationhasemergedtoapopularpracticeamongplasticsurgeonsbecausebothhighlydemandingpatientsandsurgeonsareseekingforminimally-invasiveandcostefficienttreatmentmodalitiesforandrogenicalopecia.[2]ThescientificinterestforPRPwasraisedin2006whenMishraandPavelkomanagedtodemonstratethePRPefficacyinimprovingelbowepicondylitis,reducingthetimeforhealing.[3]Sincethen,PRPlocalinjectionsstartedtobecomeverypopularwhichtransversallyinterestedmanymedicalandsurgicalbranches.[2]

PRPisanautologousproductthatismanufacturedbycentrifugationfrompatientsownvenousbloodlimitingthepotentialriskofdiseasetransmission.ComponentsofPRPincludesseveralgrowthfactors(GF),chemokines,andcytokines,suggestingthatitsbenefitsincludepromotionoftissuehealinginhard-andsoft-tissues.[45]Inanaturalenvironment,plateletsmigrateintotheinflammationsiteandreleaseAlphagranuli,whichareactivatedbyplateletsaggregationwithaconcentrationofGF.[6]Inaddition,localinjectionsofPRPareahighlyappealingtreatmentmodalitybecausetheycaneasilybeadministeredatoutpatientclinicsettings,withlowcosts.Meanwhile,rapidanduncontrolledinterestfrommedicalandnonmedicalprofessionalsmisleadtobelievePRPtobeacarrierofmesenchymal,stemcells,adipocytes,andbonemarrow,whichisobviouslynot.

Althoughthereareseveralrecentreportsandsmallrandomizedcontrolledtrials(RCT)examiningtheuseofPRPforhairlosstreatment,therearenosustainedresultsontheiroverallefficacy,[789]andnoneofthesestudieshavebeensufficientlypoweredtoassesstheriskbenefitofthismodality.[10]Despitetheheterogeneityofthesestudiesandduetothelackofthepreviousmeta-analysisspecificallyforcomparativestudiestoevaluatethisissue,weperformedawholecomprehensiveanalysishypothesizingthatPRPmightprovesignificantbenefits

inimprovingAGA.

METHODSTheobjectiveofthisreviewwastoassesstheliteratureonPRPoutcomesforAGA,withafocusonspecificclinicaloutcomesinacomparativeview,inaccordancewithPRISMAstatementforreportingthismeta-analysis.[11]Thepresentmeta-analysisisregisteredinPROSPERO,aninternationalprospectiveregisterofsystematicreviews,withthereferencecodeCRD42016041811.

Searchstrategy

AllauthorsindividuallycarriedoutafullsystematicliteraturesearchofallrecordsthroughMedline,CochraneLibrary,Embase,Scopus,GoogleScholarandResearchGateforanystudyonPRPuseforhairgrowththerapyinandrogenicalopeciafrominceptiontoAugust2017.

Thetermsemployedinthesearchwere:“androgenicalopecia,”“hairgrowth,”“hairrestoration,”“baldness,”“hairloss”combinedwith“plated-richplasma,”“PRP;”andtheywerecombinedusingBooleanoperators.Eachauthor'ssearchresultsweremerged,andduplicatecitationswerediscarded.ThesearchwasperformedaimingatthosestudiescomparingoutcomesofPRPtreatmentversuscontrolforhairrestoration.Nolanguagerestrictionswereapplied.

Studyselection

Wesearchedfor,andassessedstudiescomparinglocalinjectionsofPRPcomparedtoanycontrolforAGA.StudiestobeincludedinthisreviewhadtomatchpredeterminedcriteriaaccordingtothePICOS(patients,intervention,comparator,outcomes,andstudydesign)approach.CriteriaforinclusionandexclusionarespecifiedinTable1.Nolimitationswereappliedonethnicity,the

ageofpatientsormethodofPRPprocessing.Twoauthors(SGandPL)independentlyreviewedtheabstractsandarticles.Inaddition,thereferencelistsofallrelevantarticleswerescrutinizedaswell.

Seefulltable

Table1.Patients,intervention,comparator,outcomesandstudydesigncriteriaforinclusionandexclusionofstudies

Forthepurposeofthisanalysis,theeligiblestudieswerethosereportingonquantitativeoutcomesonPRPcomparedwithcontroltreatmentforAGA.Eachstudywasindependentlyevaluatedbyallthreeco-authors(SG,MR,PL)forinclusionorexclusionfromthisanalysis[Table1].Tobeincluded,studieshadtoprovidedetailsonbaselinecharacteristics,typeofprocedure,methodofPRPprocessing,andoutcomesonhairregrowthcomparedwithcontrolpatientsorareasinthesamepatient(internalcontrol).

Dataextraction

Datawereindependentlycollectedbytwoinvestigators(SGandPL)andcheckedbyathirdinvestigator(MR)onlyfromtheretrievedarticles.Disagreementoncollecteddatawassettledbyconsensusbetweentheseinvestigators.Noanyattemptwasmadetoobtainspecificormissingdatafromtheauthors.Thefollowingdatawereextracted:firstauthor,yearofpublication,studydesign,numberofpatients,typeofprocedure,andprimaryandsecondarymeasures.

Thequalityoftheincludedstudieswasindependentlyassessedusingthreeinvestigators(SG,MR,PL)usingtheCochraneCollaboration'sRiskofBias

AssessmenttoolforRCT[12]whileusingtheNewcastle–OttawaScaletoevaluatetheindividualnon-randomisedstudies.[13]Theresearchteamconvenedtoresolveanydisagreementontheassessmentandtoreachconsensus.

Outcomemeasures

Theprimaryoutcomewasthedifferenceinnumberofhairspersquarecentimeter.Secondaryoutcomeswerehaircross-sectionincrease,hairregrowth,andthicknesspercentageincrease.

Alloutcomesobtainedfromthestudieswerereportedwiththesamemeasurementsretrievedfromthearticles.Fromonearticle,percentageswerecalculatedfromthepatients'individualdatashowedinthepaper.[14]Thepatient'scontralateralsidewasusedascontrolinsomeoftheincludedstudies;whereaspatientswereallocatedintogroupswherePRPwaseitherusedornotintheotherstudies.Inbothcaseswereaccountedasone.Missingdataweredealtaccordingtopreviouslyvalidatedestimations.[1516]

Statisticalanalysis

StatisticalanalysiswasperformedusingReviewManager5.3software(Copenhagen:TheNordicCochraneCentre,TheCochraneCollaboration,2014).Differencesincontinuousvariableswereexpressedasmeandifference(MD)with95%confidenceinterval(CI).HeterogeneitywasassessedusingI2statistic,whichdescribesthepercentageoftotalvariationacrossstudiesthatisduetoheterogeneityratherthanchance.[17]I2valueswereevaluatedaslow,moderate,orhighat25%,50%,or75%,respectively.Toperformthemeta-analysis,theinversevariancestatisticalmethodwasusedforcontinuousoutcomevariables.Inallcases,weperformedrandom-effectanalysis,whichconsiderthevariationbothwithin-andbetweenstudies[1819]becauseoftheobservationalnatureofsomestudiesincludedinthisanalysis.AvalueofP<0.05wasconsideredtobe

statisticallysignificant.

Finally,weconductedsensitivityanalysesomittingeachstudy,inturn,usingthe“leaveoneout”methodologytodeterminewhethertheresultswereinfluencedexcessivelybyasinglestudy.Publicationbiaswasassessedusingthefunnelplotfortheprimaryoutcome.

RESULTSTheliteraturesearchyieldedsevenarticles[14202122232425]pertinenttothisissueandsourcesofinformationonoutcomesusingPRPinjectionsonscalpforAGA[Table2].TheliteraturesearchflowchartisshowninFigure1.

Seefulltable

Table2.Characteristicsoftheincludedstudies

Viewlargerversion

Figure1.Flow-chartsummarizingliteraturesearchresults

FivestudieswereRCT,[1422232425]whereastheothertwowereretrospectivestudies.[2021]

IntheRCT,theriskofbiaswaseitherloworunclearusingCochraneCollaboration'stoolforassessingtheriskofbias[

SupplementalTable1

].[12]ThenonRCTswereassessedwiththeNewcastle–OttawaScaleforriskofbiasresultingin0to4starspercategory,indicatingahightolowbias[

SupplementalTable2

].[13]Thedifficultyblindingparticipantsandresearchers,aswellas,thepresenceofinternalcontrolincreasedtheoverallriskofbias.

Theageofthepatientsrangedfrom19to63years,withafollow-upfrom3to24months.Allthestudiesshoweddifferentcentrifugationmethods[Table2].

Sixstudies,[142021232425]involvingatotalof132patients,reportedresultsonMDofnumberofhairspercm2versuscontrolandpooledanalysisshowedasignificantdifferencebetweenthetwotreatmentgroups[MD14.38,95%CI6.38–22.38,P<0.001;Figure2].Similarly,thisoutcomepersistedwhenonlythe4RCTwerepooledtogether[MD3.96,95%CI2.50–5.42,P<0.001;Figure3].

Viewlargerversion

Figure2.Forestplotshowingthesignificantlyincreasednumberofhairspercm2comparedwithco

Viewlargerversion

Figure3.Forestplotshowingthesignificantlyincreasednumberofhairspercm2comparedwithcontrolamongrandomizedcontrolledtrialstudies

Amongsecondaryoutcomes,wealsoobservedasignificantdifferencebetweenthetwotreatmentgroupsconcerningthehaircrosssectionmeasuredper10−4

mm2[MD0.22,95%CI0.07–0.38,P=0.005;Figure4]favoringPRPgroup,butthesedatawerereportedbyonly2studies.[1421]Wedidnotfoundasignificantdifferencebetweenthetwotreatmentgroupsconcerningthepercentageincreaseofhairnumber[MD18.79%,95%CI−8.50–46.08,P=0.18,Figure5]norhairthickness[MD32.63%,95%−16.23–81.48,P=0.19;Figure6].Althoughnotstatisticallysignificant,thesepooledresultsshowedatrendtowardanincreaseofhairnumber[Figure5]andhairthicknesspercentage[Figure6].

Viewlargerversion

Figure4.Forestplotshowingthesignificantlyincreasedthicknessofhairssectionexpressedas10-4/mm2comparedwithcontrol

Viewlargerversion

Figure5.Forestplotshowingthepercentageincreaseofhairnumberafterplatelet-richplasmatreatment

comparedwithcontr

Viewlargerversion

Figure6.Forestplotshowingthepercentageincreaseofhairthicknessafterplatelet-richplasmatreatmentcomparedwithcontrol

Fouroftheincludedstudies[20222324]didnotreportanyadverseeffectsorcomplicationsassociatedwithPRPinjections.Intheothertwopublications,informationaboutpossibleadverseeffectswerenotreported.

Finally,theexclusionofmoststudiesfromtheanalysisdidnotmateriallychangethesummaryestimates,withsensitivityanalysisusingthe“leaveoneout”methodology;however,significantasymmetryinthefunnelplotwasobserved

fortheprimaryoutcome[Figure7].

Viewlargerversion

Figure7.Funnelplotforbiasassessmentinhairnumberincrease

DISCUSSIONThepresentmeta-analysis,includingsixstudiesandencompassingatotalof194patients,providescompellingevidenceaboutPRPtreatmentforhairrestorationinAGA.Asignificantlyincreasednumberofhairspercm2wasobservedaftertreatmentwithPRP[Figures2and3].Furthermore,althoughtheincludedstudieshadarelativelysmalltotalnumberofpatients,wefoundinterestingresultsalsoinhaircross-sectionthicknessandothersecondaryoutcomeswhichshowedatrendtowardbenefitFigure4–Figure6.Thisisthefirstpooledanalysisonthisemergingtopic,showingoverallquantitativeoutcomes.

PRPtherapyisanappealingemergingminimallyinvasivetherapeuticmodalitytoenhancetissuehealing.Although,usedsincethemid-1990sithasrecentlygainedsubstantialincreasinginteresttoprovideacosteffectivemodalitytopromotethehealingprocess.PRPisanautologousproductthatismanufacturedfrompatientsownvenousbloodlimitingthepotentialriskofdiseasetransmission.Bydefinition,PRPcontainsconcentratedtheamountofplateletconcentration,1.000.000/ULplateletcount,3–8foldssuperioramountascomparedtothenormalperipheralblood(range150.000–350.000UL).[242526]Onactivationplateletsundergodegranulation,andrapidly,anarrayofGFsarereleasedfromplateletAlpha-granuli,[26]andGFreleaseiscontinuedinlesserextenduptoseveraldays.[2728]PRPalsocontainsplasmaandover20GFs,whichincludeplatelet-derivedendothelialGF,transformingGF–β,fibroblast

GF–2,vascularendothelialGF,epidermalGF,insulin-likeGF–1,and,inaddition,thrombin,whichhasbiologicalandadhesiveproperties.[29]IthasalsobeenreportedthatPRPinducesoverexpressionendogenousexpressionofGFs.[3031]Throughthecomplexinteractionofgrowthanddifferentiationfactorsandalongwithadhesiveproteinfactors,PRPisbelievedtostimulatehealingbypromotingregenerativechemotaxis,cellproliferation,angiogenesis,extracellularmatrixformation,andcollagensynthesis.[3233]

ThereisnoastandardizedmethodforPRPpreparation,therefore,theremightbedifferencesinproductcomposition.ThisfactmayleadtoanalteredPRPfunction,whichmightexplainthecontroversyfoundintotheliterature.Furthermore,differencesinPRPcompositionresultfromdifferencesinthesamplesretrievedfrompersontoperson.Differencesinthemanufacturingoftheinoculateresult,especiallyfromtheroutineofcentrifugationandwhethereitherbovinethrombinorcalciumchlorideisusedinactivation.[1027]Theusedendproductmayvarybytheusedvolumeandthenumberofinjectionsadministered,aswellasthecolor,plateletcount,thenumberorabsenceofleukocytes,anditsproteincontent.[27]

Recently,anumberofreportshavebeenpublishedshowingpromisingresultsforthetreatmentofAGA.Unfortunately,thesestudiesweregenerallysmall,poorlycontrolled,withoutoutcomes'objectiveandmeasuredquantificationandtherefore,theywerenotincludedinthismeta-analysis.Betsietal.[8]treated42alopeciapatientswithPRP,fivetimesduringover2monthsshowinganimprovementinhairpullingtestandahighoverallpatientsatisfaction.Indeed,theyfoundin31%ofcasessomedrowsinessandsensiblescalp.Schiavoneetal.[9]performedthelargeststudyonthistopic,including64malepatientswithAGAandtheyweretreatedwitharegimenofPRPenrichedwithleukocytesinadditiontoconcentratedplasmaproteins.Twosequentialinjectionswere

performedatinitiationofthestudyandsubsequentlyatthreemonths.Theevaluationwasperformedonthebasisofglobalassessmentofbeforeandafterphotographsbyunblindedassessorsshowinganimprovementinappearancefor62ofthe64patients.[9]Anothernoncontrolled,nonblindedstudyof22patientsfoundanincreaseintotalhairdensityfromameanof143.1atbaselinetoamaximumof170.7hairs/cm2at3monthsfollow-up.[34]Anothernoncontrolled,nonblindedstudyof11patients[35]detectedasignificantreductioninhairlossbetweenfirstandfourthinjection.Particularly,haircountincreasedfromanaveragenumberof71hairfollicularunitsto93hairfollicularunits,withanegativepulltestwasin9patients.[35]

Singhaletal.[36]performedasimilarstudyon10patientsalsoshowingclinicalimprovementinthehaircounts,thicknessandrootstrength.Theyindeedhadthreepatientscomplainingamildheadacheaftertheinitialprocedure.Morerecently,Navarroetal.[9]reportedanoverallincreaseofhairdensityandanincreaseof6.2%anagenhairfollicleswhileadecreaseof5.1%amongtelogenoneson100patientstreatedwithPRP,similarlytoAlvesandGrimalt[24]Wedidnotattempttopoolthedataexistingonhairfolliclecycles,astheywerenotconsistentamongtheincludedstudies.Nonetheless,PRPshowedpromisingresultsalsocombinedwithhairfolliculartransplanttoenhancethepostoperativeoutcomes.[3738]Particularly,UebelstudiedashortseriesofpatientscomparingtwoareasofhairtransplantwithorwithoutPRPintherootofthegrafts.Twoareas(2.5cm2)weremarkedonthescalpandeachplantedwith20grafts/cm2.After1year,theareaimplantedwiththePRP-enrichedgraftsdemonstratedahigherfollicleunitssurvivalrateanddensity.Inamurinemodel,Miaoetal.[39]demonstratedsomeinfluenceofPRPonhairregrowthwhensimultaneouslyinjectedwithtransplantedhairfollicles,withconsistentdata,furtherencouragingclinicalapplications.Again,thedataaboutPRPandhairgrowth,togetherwithasurgicalhairtransplant,aresparseandheterogeneousalthoughpromising.

Nevertheless,theseoutcomescanbeexplainedbythephysiologicalroleofplateletsdegranulationduringinflammation,whichisstimulatedbysurgicalhairtransplantation,atraumaticeventcausinginflammatoryresponseandchemotaxis.[3]Forthisreason,webelievethatsurgicaltransplantationofhairfollicleswithPRPmightbemoreeffectivethatPRPalone.

Theresultsofthismeta-analysisshouldbeviewedinlightofanumberoflimitationsandpotentialbiasinfluencingthesefindings.Onlysixstudieswereusedforthispooledanalysis,onlyfourofthemwererandomizedcontrolledtrial[1422232425]andtwowereobservational[2021]withclearheterogeneityinmethodsandsettings[Table2].WewantedtoincludeonlycomparativestudiestobetterassesstheefficacyofPRP,missingtheoutcomesofone-armstudies.

Thenumberofpatientsconsideredwasextremelysmallandthereweredifferencesinpatients'age,devicesused,centrifugationmethods,control,andareasoftreatment,whichmightbeaconfoundingfactorfortheresults.

Importantstatisticalheterogeneity(I2>75%)wasfoundinallanalysisFigure2–Figure6,showingimportantdifferencesinmethodsandstudysettings.However,theexclusionofanystudyfromtheanalysisdidnotmateriallychangethesummaryestimates,butfunnelplotfortheprimaryoutcomesshowedsignificantasymmetry,whichindicatesthatpublicationbiasmighthavesomehowinfluencedtheresults.

Othermajorlimitationsofthispooledanalysesincludethefactthatmostoftheincludedstudiesusedinternalcontrols,wherethepatient'scontralateralsideorotherareasservedasitsowncontrol,whereasinothers,patientswererandomizedintogroupswherePRPwaseitherusedornotused[Table2].Thereweredifferencesinthetreatedscalpareasandinsomecases,thecontrolgroupwastreatedwithplacentalextract[21]ordalteparinandprotaminecontaining

microparticles[14]withnoplacebocontrol.

CONCLUSIONPRPinjectionforlocalhairrestorationinpatientswithAGAseemstoincreasehairsnumberandthicknesswithminimalornocollateraleffects.However,thecurrentevidencedoesnotsupportthistreatmentsmodalityoverothertreatmentsduetothelackofclinicalevidence,establishedprotocols(i.e.,numberofsessions,centrifugation,zonestobeinjected,etc.),andlong-termfollow-upoutcomes.

Theresultsofthismeta-analysisshouldbeinterpretedwithcautionbecauseitincludespoolingmanysmallstudiesandlargerrandomizedstudiesshouldbeperformedtoverifythisperception.Themedicalliteraturedoesnotconfirmthatthetreatmentisscientificallyrelevant.TheadditionofPRPmightbeusefulinimprovingtheoutcomesofhairtransplantationprocedures,butthereisnoevidencewhetherPRPismoreeffectivethanminoxidilorfinasteridetreatments.Largerstudieswithlong-termfollow-uparewarrantedtovalidatethispromisingtreatmentmodality.

Financialsupportandsponsorship

Nil.

Conflictsofinterest

Therearenoconflictsofinterest.

ArticlesfromInternationalJournalofTrichologyareprovidedherecourtesyofWoltersKluwer--MedknowPublications

PMCCopyrightNotice

ThearticlesavailablefromthePMCsiteareprotectedbycopyright,eventhoughaccessisfree.CopyrightisheldbytherespectiveauthorsorpublisherswhoprovidethesearticlestoPMC.UsersofPMCareresponsibleforcomplyingwiththetermsandconditionsdefinedbythecopyrightholder.

UsersshouldassumethatstandardcopyrightprotectionappliestoarticlesinPMC,unlessanarticlecontainsanexplicitlicensestatementthatgivesauseradditionalreuseorredistributionrights.PMCdoesnotallowautomated/bulkdownloadingofarticlesthathavestandardcopyrightprotection.

SeethecopyrightnoticeonthePMCsite,https://www.ncbi.nlm.nih.gov/pmc/about/copyright/,forfurtherdetailsandspecificexceptions.

REFERENCES1. TabolliS,SampognaF,diPietroC,MannooranparampilTJ,RibuffoM,AbeniD,etal.,authors.

Healthstatus,copingstrategies,andalexithymiainsubjectswithandrogeneticalopecia:Aquestionnairestudy.AmJClinDermatol.2013;14:139–45.[PubMed]

2. EppleyBL,PietrzakWS,BlantonM,authors.Platelet-richplasma:Areviewofbiologyandapplicationsinplasticsurgery.PlastReconstrSurg.2006;118:147e–59e

3. MishraA,PavelkoT,authors.Treatmentofchronicelbowtendinosiswithbufferedplatelet-richplasma.AmJSportsMed.2006;34:1774–8.[PubMed]

4. HammondJW,HintonRY,CurlLA,MurielJM,LoveringRM,authors.Useofautologousplatelet-richplasmatotreatmusclestraininjuries.AmJSportsMed.2009;37:1135–42.[PubMed]

5. VirchenkoO,AspenbergP,authors.Howcanoneplateletinjectionaftertendoninjuryleadtoastrongertendonafter4weeks?Interplaybetweenearlyregenerationandmechanicalstimulation.ActaOrthop.2006;77:806–12.[PubMed]

6. PetrungaroPS,author.Usingplatelet-richplasmatoacceleratesofttissuematurationinestheticperiodontalsurgery.CompendContinEducDent.2001;22:729–32.734736[PubMed]

7. SchiavoneG,RaskovicD,GrecoJ,AbeniD,authors.Platelet-richplasmaforandrogeneticalopecia:Apilotstudy.DermatolSurg.2014;40:1010–9.[PubMed]

8. BetsiEE,GermainE,KalbermattenDF,TrempM,EmmeneggerV,authors.Platelet-richplasmainjectioniseffectiveandsafeforthetreatmentofalopecia.EurJPlastSurg.2013;36:407–12

9. NavarroMR,AsínM,MartínezMA,MartinezAM,MolinaC,MoscosoL,etal.,authors.Managementofandrogeneticalopecia:Acomparativeclinicalstudybetweenplasmarichingrowth

factorsandtopicalminoxidil.EurJPlastSurg.2016;1:1–8

10. LeoMS,KumarAS,KiritR,KonathanR,SivamaniRK,authors.Systematicreviewoftheuseofplatelet-richplasmainaestheticdermatology.JCosmetDermatol.2015;14:315–23.[PubMed]

11. MoherD,LiberatiA,TetzlaffJ,AltmanDG,authors;PRISMAGroup.Preferredreportingitemsforsystematicreviewsandmeta-analyses:ThePRISMAstatement.IntJSurg.2010;8:336–41.[PubMed]

12. HigginsJP,AltmanDG,GøtzschePC,JüniP,MoherD,OxmanAD,etal.,authors.Thecochranecollaboration'stoolforassessingriskofbiasinrandomisedtrials.BMJ.2011;343:d5928[PubMed]

13. WellsGA,SheaB,O'ConnellD,PetersonJ,WelchV,LososM,etal.,authors.TheNewcastle-OttawaScaleforAssessingtheQualityofNonrandomisedStudiesinMeta-Analyses.2014Lastaccessedon2016Jun28.Availablefrom:http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp.

14. TakikawaM,NakamuraS,NakamuraS,IshiraraM,KishimotoS,SasakiK,etal.,authors.Enhancedeffectofplatelet-richplasmacontaininganewcarrieronhairgrowth.DermatolSurg.2011;37:1721–9.[PubMed]

15. FurukawaTA,BarbuiC,CiprianiA,BrambillaP,WatanabeN,authors.Imputingmissingstandarddeviationsinmeta-analysescanprovideaccurateresults.JClinEpidemiol.2006;59:7–10.[PubMed]

16. HozoSP,DjulbegovicB,HozoI,authors.Estimatingthemeanandvariancefromthemedian,range,andthesizeofasample.BMCMedResMethodol.2005;5:13[PubMed]

17. MantelN,HaenszelW,authors.Statisticalaspectsoftheanalysisofdatafromretrospectivestudiesofdisease.JNatlCancerInst.1959;22:719–48.[PubMed]

18. HigginsJP,ThompsonSG,DeeksJJ,AltmanDG,authors.Measuringinconsistencyinmeta-analyses.BMJ.2003;327:557–60.[PubMed]

19. DerSimonianR,LairdN,authors.Meta-analysisinclinicaltrials.ControlClinTrials.1986;7:177–88.[PubMed]

20. CervelliV,GarcovichS,BielliA,CervelliG,CurcioBC,ScioliMG,etal.,authors.Theeffectofautologousactivatedplateletrichplasma(AA-PRP)injectiononpatternhairloss:Clinicalandhistomorphometricevaluation.BiomedResInt.2014;2014:760709[PubMed]

21. KangJS,ZhengZ,ChoiMJ,LeeSH,KimDY,ChoSB,etal.,authors.TheeffectofCD34+cell-containingautologousplatelet-richplasmainjectiononpatternhairloss:Apreliminarystudy.JEurAcadDermatolVenereol.2014;28:72–9.[PubMed]

22. LeeSH,ZhengZ,KangJS,KimDY,OhSH,ChoSB,etal.,authors.Therapeuticefficacyofautologousplatelet-richplasmaandpolydeoxyribonucleotideonfemalepatternhairloss.WoundRepairRegen.2015;23:30–6.[PubMed]

23. GentileP,GarcovichS,BielliA,ScioliMG,OrlandiA,CervelliV,etal.,authors.Theeffectof

platelet-richplasmainhairregrowth:ARandomizedplacebo-controlledtrial.StemCellsTranslMed.2015;4:1317–23.[PubMed]

24. AlvesR,GrimaltR,authors.Randomizedplacebo-controlled,double-blind,half-headstudytoassesstheefficacyofplatelet-richplasmaonthetreatmentofandrogeneticalopecia.DermatolSurg.2016;42:491–7.[PubMed]

25. MaparMA,ShahriariS,HaghighizadehMH,authors.Efficacyofplatelet-richplasmainthetreatmentofandrogenetic(male-patterned)alopecia:Apilotrandomizedcontrolledtrial.JCosmetLaserTher.2016;18:452–5.[PubMed]

26. FosterTE,PuskasBL,MandelbaumBR,GerhardtMB,RodeoSA,authors.Platelet-richplasma:Frombasicsciencetoclinicalapplications.AmJSportsMed.2009;37:2259–72.[PubMed]

27. WroblewskiAP,MeliaHJ,WrightVJ,authors.Applicationofplatelet-richplasmatoenhancetissuerepair.OperTechOrthop.2010;20:98–105

28. NguyenRT,Borg-SteinJ,McInnisK,authors.Applicationsofplatelet-richplasmainmusculoskeletalandsportsmedicine:Anevidence-basedapproach.PMR.2011;3:226–50.[PubMed]

29. MarxRE,author.Platelet-richplasma:Evidencetosupportitsuse.JOralMaxillofacSurg.2004;62:489–96.[PubMed]

30. AnituaE,SánchezM,NurdenAT,NurdenP,OriveG,AndíaI,etal.,authors.Newinsightsintoandnovelapplicationsforplatelet-richfibrintherapies.TrendsBiotechnol.2006;24:227–34.[PubMed]

31. deMosM,vanderWindtAE,JahrH,vanSchieHT,WeinansH,VerhaarJA,etal.,authors.Canplatelet-richplasmaenhancetendonrepair?Acellculturestudy.AmJSportsMed.2008;36:1171–8.[PubMed]

32. LyrasDN,KazakosK,AgrogiannisG,VerettasD,KokkaA,KiziridisG,etal.,authors.Experimentalstudyoftendonhealingearlyphase:IsIGF-1expressioninfluencedbyplateletrichplasmagel?OrthopTraumatolSurgRes.2010;96:381–7.[PubMed]

33. LeeKS,WilsonJJ,RabagoDP,BaerGS,JacobsonJA,BorreroCG,etal.,authors.Musculoskeletalapplicationsofplatelet-richplasma:Fadorfuture?AJRAmJRoentgenol.2011;196:628–36.[PubMed]

34. GkiniMA,KouskoukisAE,TripsianisG,RigopoulosD,KouskoukisK,authors.Studyofplatelet-richplasmainjectionsinthetreatmentofandrogeneticalopeciathroughanone-yearperiod.JCutanAesthetSurg.2014;7:213–9.[PubMed]

35. KhatuSS,MoreYE,GokhaleNR,ChavhanDC,BendsureN,authors.Platelet-richplasmainandrogenicalopecia:Mythoraneffectivetool.JCutanAesthetSurg.2014;7:107–10.[PubMed]

36. SinghalP,AgarwalS,DhotPS,SayalSK,authors.Efficacyofplatelet-richplasmaintreatmentofandrogenicalopecia.AsianJTransfusSci.2015;9:159–62.[PubMed]

37. UebelCO,daSilvaJB,CantarelliD,MartinsP,authors.Theroleofplateletplasmagrowthfactorsinmalepatternbaldnesssurgery.PlastReconstrSurg.2006;118:1458–66.[PubMed]

38. ParkKY,KimHK,KimBJ,KimMN,authors.Letter:Platelet-richplasmafortreatingmalepatternbaldness.DermatolSurg.2012;38:2042–4.[PubMed]

39. MiaoY,SunYB,SunXJ,DuBJ,JiangJD,HuZQ,etal.,authors.Promotionaleffectofplatelet-richplasmaonhairfolliclereconstitutioninvivo.DermatolSurg.2013;39:1868–76.[PubMed]

[Back]

Table1.Patients,intervention,comparator,outcomesandstudydesigncriteriaforinclusionandexclusionofstudies

[Back]

[Back]

Table2.Characteristicsoftheincludedstudies

[Back]

[Back]

Figure1.Flow-chartsummarizingliteraturesearchresults

[Back]

[Back]

Figure2.Forestplotshowingthesignificantlyincreasednumberofhairspercm2comparedwithco

[Back]

[Back]

Figure3.Forestplotshowingthesignificantlyincreasednumberofhairspercm2comparedwithcontrolamongrandomizedcontrolledtrialstudies

[Back]

[Back]

Figure4.

Forestplotshowingthesignificantlyincreasedthicknessofhairssectionexpressedas10-4/mm2comparedwithcontrol

[Back]

[Back]

Figure5.Forestplotshowingthepercentageincreaseofhairnumberafterplatelet-richplasmatreatmentcomparedwithcontr

[Back]

[Back]

Figure6.Forestplotshowingthepercentageincreaseofhairthicknessafterplatelet-richplasmatreatmentcomparedwithcontrol

[Back]

[Back]

Figure7.Funnelplotforbiasassessmentinhairnumberincrease

[Back]